Skip to content
Cancer Regulation and Immunology

Rautajoki lab

Publications

2024

  1. Governa, V, de Oliveira, KG, Bång-Rudenstam, A, Offer, S, Cerezo-Magaña, M, Li, J et al.. Protumoral lipid droplet-loaded macrophages are enriched in human glioblastoma and can be therapeutically targeted. Sci Transl Med. 2024;16 (771):eadk1168. doi: 10.1126/scitranslmed.adk1168. PubMed PMID:39475570 .
  2. Huhtala, L, Karabiyik, G, Rautajoki, KJ. Development and epigenetic regulation of Atypical teratoid/rhabdoid tumors in the context of cell-of-origin and halted cell differentiation. Neurooncol Adv. 2024;6 (1):vdae162. doi: 10.1093/noajnl/vdae162. PubMed PMID:39465218 PubMed Central PMC11502914.
  3. Nurminen, R, Afyounian, E, Paunu, N, Katainen, R, Isomäki, M, Nurminen, A et al.. Previously reported CCDC26 risk variant and novel germline variants in GALNT13, AR, and MYO10 associated with familial glioma in Finland. Sci Rep. 2024;14 (1):11562. doi: 10.1038/s41598-024-62296-5. PubMed PMID:38773237 PubMed Central PMC11109329.
  4. Pekkarinen, M, Nordfors, K, Uusi-Mäkelä, J, Kytölä, V, Hartewig, A, Huhtala, L et al.. Aberrant DNA methylation distorts developmental trajectories in atypical teratoid/rhabdoid tumors. Life Sci Alliance. 2024;7 (6):. doi: 10.26508/lsa.202302088. PubMed PMID:38499326 PubMed Central PMC10948937.
  5. Kivioja, T, Posti, JP, Sipilä, J, Rauhala, M, Frantzén, J, Gardberg, M et al.. Motor dysfunction as a primary symptom predicts poor outcome: multicenter study of glioma symptoms. Front Oncol. 2023;13 :1305725. doi: 10.3389/fonc.2023.1305725. PubMed PMID:38239655 PubMed Central PMC10794640.

Search PubMed

2023
  1. Kivioja, T, Posti, JP, Sipilä, J, Rauhala, M, Frantzén, J, Gardberg, M et al.. Motor dysfunction as a primary symptom predicts poor outcome: multicenter study of glioma symptoms. Front Oncol. 2023;13 :1305725. doi: 10.3389/fonc.2023.1305725. PubMed PMID:38239655 PubMed Central PMC10794640.
  2. Lin, J, Moradi, E, Salenius, K, Lehtipuro, S, Häkkinen, T, Laiho, JE et al.. Distinct transcriptomic profiles in children prior to the appearance of type 1 diabetes-linked islet autoantibodies and following enterovirus infection. Nat Commun. 2023;14 (1):7630. doi: 10.1038/s41467-023-42763-9. PubMed PMID:37993433PubMed Central PMC10665402.
  3. Rautajoki, KJ, Jaatinen, S, Hartewig, A, Tiihonen, AM, Annala, M, Salonen, I et al.. Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting. Acta Neuropathol Commun. 2023;11 (1):176. doi: 10.1186/s40478-023-01669-9. PubMed PMID:37932833 PubMed Central PMC10629206.
  4. Alanen, E, Heikkinen, S, Nurminen, R, Nykter, M, Haapasalo, H, Hirvonen, E et al.. Early-onset grade 2-3 diffuse gliomas and schwannomas increase the risk of central nervous system tumors among the patients’ relatives. Neurooncol Adv. 2023;5 (1):vdad008. doi: 10.1093/noajnl/vdad008. PubMed PMID:36950216 PubMed Central PMC10025807.

Search PubMed

2022
  1. Rautajoki, KJ, Jaatinen, S, Tiihonen, AM, Annala, M, Vuorinen, EM, Kivinen, A et al.. PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas. Sci Rep. 2022;12 (1):14083. doi: 10.1038/s41598-022-14977-2. PubMed PMID:35982066 PubMed Central PMC9388569.

Search PubMed

2021
  1. Taavitsainen, S, Engedal, N, Cao, S, Handle, F, Erickson, A, Prekovic, S et al.. Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse. Nat Commun. 2021;12 (1):5307. doi: 10.1038/s41467-021-25624-1. PubMed PMID:34489465 PubMed Central PMC8421417.
  2. Kukkonen, K, Taavitsainen, S, Huhtala, L, Uusi-Makela, J, Granberg, KJ, Nykter, M et al.. Chromatin and Epigenetic Dysregulation of Prostate Cancer Development, Progression, and Therapeutic Response. Cancers (Basel). 2021;13 (13):. doi: 10.3390/cancers13133325. PubMed PMID:34283056 PubMed Central PMC8268970.
  3. Filppu, P, Tanjore Ramanathan, J, Granberg, KJ, Gucciardo, E, Haapasalo, H, Lehti, K et al.. CD109-GP130 interaction drives glioblastoma stem cell plasticity and chemoresistance through STAT3 activity. JCI Insight. 2021;6 (9):. doi: 10.1172/jci.insight.141486. PubMed PMID:33986188 PubMed Central PMC8262342.
  4. Rajamäki, K, Taira, A, Katainen, R, Välimäki, N, Kuosmanen, A, Plaketti, RM et al.. Genetic and Epigenetic Characteristics of Inflammatory Bowel Disease-Associated Colorectal Cancer. Gastroenterology. 2021;161 (2):592-607. doi: 10.1053/j.gastro.2021.04.042. PubMed PMID:33930428 .

Search PubMed

2020
  1. Dufva, O, Pölönen, P, Brück, O, Keränen, MAI, Klievink, J, Mehtonen, J et al.. Immunogenomic Landscape of Hematological Malignancies. Cancer Cell. 2020;38 (3):424-428. doi: 10.1016/j.ccell.2020.08.019. PubMed PMID:32931743 .
  2. Yang, M, Petralia, F, Li, Z, Li, H, Ma, W, Song, X et al.. Community Assessment of the Predictability of Cancer Protein and Phosphoprotein Levels from Genomics and Transcriptomics. Cell Syst. 2020;11 (2):186-195.e9. doi: 10.1016/j.cels.2020.06.013. PubMed PMID:32710834 .
  3. Dufva, O, Pölönen, P, Brück, O, Keränen, MAI, Klievink, J, Mehtonen, J et al.. Immunogenomic Landscape of Hematological Malignancies. Cancer Cell. 2020;38 (3):380-399.e13. doi: 10.1016/j.ccell.2020.06.002. PubMed PMID:32649887 .
  4. Doan, P, Musa, A, Murugesan, A, Sipilä, V, Candeias, NR, Emmert-Streib, F et al.. Glioblastoma Multiforme Stem Cell Cycle Arrest by Alkylaminophenol Through the Modulation of EGFR and CSC Signaling Pathways. Cells. 2020;9 (3):. doi: 10.3390/cells9030681. PubMed PMID:32164385 PubMed Central PMC7140667.
  5. Granberg, KJ, Raita, A, Lehtinen, B, Tiihonen, AM, Kesseli, J, Annala, M et al.. Moderate-to-strong expression of FGFR3 and TP53 alterations in a subpopulation of choroid plexus tumors. Histol Histopathol. 2020;35 (7):673-680. doi: 10.14670/HH-18-180. PubMed PMID:31660579 .

Search PubMed

2019
  1. Granberg, KJ, Raita, A, Lehtinen, B, Tiihonen, AM, Kesseli, J, Annala, M et al.. Moderate-to-strong expression of FGFR3 and TP53 alterations in a subpopulation of choroid plexus tumors. Histol Histopathol. 2020;35 (7):673-680. doi: 10.14670/HH-18-180. PubMed PMID:31660579 .
  2. Pölönen, P, Mehtonen, J, Lin, J, Liuksiala, T, Häyrynen, S, Teppo, S et al.. Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies. Cancer Res. 2019;79 (10):2466-2479. doi: 10.1158/0008-5472.CAN-18-2970. PubMed PMID:30940663 .
  3. Lehtipuro, S, Nykter, M, Granberg, KJ. Modes of immunosuppression in glioblastoma microenvironment. Oncotarget. 2019;10 (9):920-921. doi: 10.18632/oncotarget.26643. PubMed PMID:30847018 PubMed Central PMC6398170.

Search PubMed

2018
  1. Luoto, S, Hermelo, I, Vuorinen, EM, Hannus, P, Kesseli, J, Nykter, M et al.. Computational Characterization of Suppressive Immune Microenvironments in Glioblastoma. Cancer Res. 2018;78 (19):5574-5585. doi: 10.1158/0008-5472.CAN-17-3714. PubMed PMID:29921698 .
  2. Nordfors, K, Haapasalo, J, Afyounian, E, Tuominen, J, Annala, M, Häyrynen, S et al.. Erratum: Whole-exome sequencing identifies germline mutation in TP53 and ATRX in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. Cold Spring Harb Mol Case Stud. 2018;4 (3):. doi: 10.1101/mcs.a003129. PubMed PMID:29858379 PubMed Central PMC5983177.
  3. Nordfors, K, Haapasalo, J, Afyounian, E, Tuominen, J, Annala, M, Häyrynen, S et al.. Whole-exome sequencing identifies germline mutation in TP53 and ATRX in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. Cold Spring Harb Mol Case Stud. 2018;4 (2):. doi: 10.1101/mcs.a002246. PubMed PMID:29602769 PubMed Central PMC5880256.
  4. Haapasalo, J, Nordfors, K, Granberg, KJ, Kivioja, T, Nykter, M, Haapasalo, H et al.. NRF2, DJ1 and SNRX1 and their prognostic impact in astrocytic gliomas. Histol Histopathol. 2018;33 (8):791-801. doi: 10.14670/HH-11-973. PubMed PMID:29441509 .

Search PubMed

2017
  1. Lehtinen, B, Raita, A, Kesseli, J, Annala, M, Nordfors, K, Yli-Harja, O et al.. Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas. BMC Cancer. 2017;17 (1):310. doi: 10.1186/s12885-017-3274-9. PubMed PMID:28468611 PubMed Central PMC5415775.
  2. Granberg, KJ, Annala, M, Lehtinen, B, Kesseli, J, Haapasalo, J, Ruusuvuori, P et al.. Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas. Neuro Oncol. 2017;19 (9):1206-1216. doi: 10.1093/neuonc/nox028. PubMed PMID:28379477 PubMed Central PMC5570261.

Search PubMed